Sana Biotechnology, Inc. (NASDAQ:SANA) Stock Has Average Target Price of $9.33 According to Brokerages

Sana Biotechnology, Inc. (NASDAQ:SANA) has been assigned a consensus rating of “Moderate Buy” from the ten analysts that are currently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company. The average 1-year target price among analysts that have issued ratings on the stock in the last year is $9.33.

Several analysts recently issued reports on the company. Bank of America lowered their price target on Sana Biotechnology from $7.00 to $6.00 and set a “buy” rating for the company in a report on Friday, August 14th. TD Cowen raised Sana Biotechnology to a “strong-buy” rating in a research report on Monday, August 24th. Wall Street Zen cut Sana Biotechnology from a “hold” rating to a “sell” rating in a report on Monday, July 20th. Finally, Weiss Ratings upgraded Sana Biotechnology from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, July 23rd.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. BlackRock Inc. acquired a new stake in Sana Biotechnology during the 2nd quarter valued at approximately $58,196,000. Canada Pension Plan Investment Board acquired a new position in shares of Sana Biotechnology in the 2nd quarter valued at approximately $35,662,000. Bank of America Corp DE acquired a new position in shares of Sana Biotechnology in the 2nd quarter valued at approximately $20,062,000. Alphabet Inc. acquired a new position in shares of Sana Biotechnology in the 2nd quarter valued at approximately $9,816,000. Finally, Deutsche Bank AG purchased a new position in shares of Sana Biotechnology during the 2nd quarter valued at approximately $2,251,000. 88.23% of the stock is owned by institutional investors and hedge funds.

Sana Biotechnology Stock Down 8.1%

Shares of Sana Biotechnology stock traded down $0.20 during trading hours on Friday, hitting $2.27. The company’s stock had a trading volume of 3,088,484 shares, compared to its average volume of 3,840,626. Sana Biotechnology has a 1-year low of $2.25 and a 1-year high of $5.90. The business has a fifty day moving average of $3.30 and a 200 day moving average of $3.29. The company has a market capitalization of $679.55 million, a PE ratio of -2.99 and a beta of 2.18.

Sana Biotechnology (NASDAQ:SANA) last issued its earnings results on Monday, August 10th. The company reported ($0.13) EPS for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.02. On average, sell-side analysts anticipate that Sana Biotechnology will post -0.72 earnings per share for the current fiscal year.

Sana Biotechnology Company Profile

Sana Biotechnology, Inc is a biotechnology company focused on developing engineered cell and gene therapies intended to treat diseases with significant unmet medical needs. The company’s approach is designed to enable the delivery of functional cells or genetic material to patients while addressing challenges such as immune rejection, manufacturing complexity and the need for repeated treatment.

Sana’s research programs include both ex vivo therapies, in which cells are modified outside the body before being administered to a patient, and in vivo therapies, which are designed to modify or deliver therapeutic material directly within the body.